ATPW
TCRT icon

Ashton Thomas Private Wealth’s Alaunos Therapeutics TCRT Stock Holding History

Ashton Thomas Private Wealth’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$3 – 1704
2024
Q2 		$3 Buy
+1
New +$12 ﹤0.01% 1929

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

Ashton Thomas Private Wealth's TCRT Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 1 share — an estimated $3 sold.

Ashton Thomas Private Wealth first reported a position in TCRT in Q2 2024 and held it in 1 quarter. The position peaked at $3 in Q2 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 1 Alaunos Therapeutics share in Q3 2024, an estimated $3.
  • Ashton Thomas Private Wealth first reported a position in Alaunos Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's Alaunos Therapeutics position peaked at $3 in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.